NewAmsterdam Pharma (NASDAQ:NAMS) Director Purchases $31,487.40 in Stock

Key Points

• Director James Topper of NewAmsterdam Pharma purchased 1,260 shares at an average price of $24.99, increasing his total ownership to 3,027,864 shares valued at approximately $75.67 million.
• The stock price of NewAmsterdam Pharma has recently increased, trading up 1.1% to $26.90, with a 12-month range between $14.06 and $27.29.
• Analyst ratings for NewAmsterdam Pharma are largely positive, with several firms maintaining buy ratings and a consensus price target of $41.55.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 1,260 shares of the stock in a transaction on Monday, September 8th. The shares were purchased at an average cost of $24.99 per share, with a total value of $31,487.40. Following the transaction, the director directly owned 3,027,864 shares of the company's stock, valued at approximately $75,666,321.36. This trade represents a 0.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded down $0.07 during mid-day trading on Monday, reaching $24.12. The company's stock had a trading volume of 1,037,570 shares, compared to its average volume of 968,191. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $27.35. The firm's fifty day moving average price is $23.67 and its two-hundred day moving average price is $20.82.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The business had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price target for the company. Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Finally, Citigroup assumed coverage on NewAmsterdam Pharma in a research note on Tuesday, June 17th. They set a "buy" rating and a $42.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of "Moderate Buy" and an average price target of $41.55.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in NewAmsterdam Pharma during the 1st quarter valued at approximately $25,000. GF Fund Management CO. LTD. purchased a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in NewAmsterdam Pharma by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company's stock valued at $79,000 after buying an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in NewAmsterdam Pharma by 130.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after buying an additional 3,390 shares in the last quarter. Finally, Avanza Fonder AB bought a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at approximately $127,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.